EVEREST Outcome Trial. JAMA 2007; 297: 1319.
Background: Vasopressin mediates fluid retention in heart failure. Tolvaptan, a vasopressin V2 receptor blocker may be an effective adjunct in the management of heart failure.
Methods: Multicenter, randomized, double-blind, placebo controlled study. N = 4133.
Treatment: Oral tolvaptan 30 mg daily vs placebo for 60 days.
Results:
Primary Outcome: mortality 25.9% v 26.3%, p = 0.68, no difference
Secondary Outcomes:
cardiovascular mortality: no difference
cardiovascular death or hospitalization: no difference
worsening heart failure: no difference
Leave a comment